Truist Securities Reiterates Buy on Gilead Sciences, Maintains $91 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Gilead Sciences (NASDAQ:GILD) and maintained a price target of $91.
September 06, 2023 | 4:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated a 'Buy' rating on Gilead Sciences and maintained a price target of $91.
The reiteration of a 'Buy' rating by Truist Securities indicates a positive outlook for Gilead Sciences. The maintained price target of $91 suggests that the analyst believes the stock has potential for growth. This could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100